|
1
|
Chavan S, Bray F, Lortet-Tieulent J,
Goodman M and Jemal A: International variations in bladder cancer
incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sievert KD, Amend B, Nagele U, Schilling
D, Bedke J, Horstmann M, Hennenlotter J, Kruck S and Stenzl A:
Economic aspects of bladder cancer: What are the benefits and
costs? World J Urol. 27:295–300. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colombo R, Hurle R, Moschini M, Freschi M,
Colombo P, Colecchia M, Ferrari L, Lucianò R, Conti G, Magnani T,
et al: Feasibility and clinical roles of different substaging
systems at first and second transurethral resection in patients
with T1 high-grade bladder cancer. Eur Urol Focus. 4:87–93. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al: EAU guidelines on non-muscle-invasive
urothelial carcinoma of bladder: Update 2013. Eur Urol. 64:639–653.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Proctor I, Stoeber K and Williams GH:
Biomarkers in bladder cancer. Histopathology. 57:1–13. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goodison S, Rosser CJ and Urquidi V:
Bladder cancer detection and monitoring: Assessment of urine- and
blood-based marker tests. Mol Diagn Ther. 17:71–84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Rhijn BW, Burger M, Lotan Y, Solsona
E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and
progression of disease in non-muscle-invasive bladder cancer: From
epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fransen van de Putte EE, Behrendt MA,
Pigot GL, van der Kwast TH and van Rhijn BW: Prognostic
significance of substage and WHO classification systems in T1
urothelial carcinoma of the bladder. Curr Opin Urol. 25:427–435.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kitamura H and kakehi Y: Treatment and
management of high-grade T1 bladder cancer: What should we do after
second TUR? Jpn J Clin Oncol. 45:315–322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernandez-Gomez J, Madero R, Solsona E,
Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa
C, Rodriguez-Molina J, et al: Predicting non-muscle invasive
bladder cancer recurrence and progression in patients treated with
bacillus Calmette-Guerin: The CUETO scoring model. J Urol.
182:2195–2203. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song K, Shi X, Wang H, Zou F, Lu F, Ma X,
Xia X and Jiang J: Can a nomogram help to predict the overall and
cancer-specific survival of patients with chondrosarcoma? Clin
Orthop Relat Res. 476:987–996. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang C, Wang W, Feng X, Sun J, Zhang Y,
Zeng Y, Wang J, Chen H, Cai M, Lin J, et al: Nomogram individually
predicts the overall survival of patients with
gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer.
117:1544–1550. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong F, Shen Y, Gao F, Shi X, Xu T, Wang
X, Zhang X, Zhong S, Zhang M, Chen S and Shen Z: Nomograms to
predict individual prognosis of patients with primary small cell
carcinoma of the bladder. J Cancer. 9:1152–1164. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC cancer staging manual. 8th. New York:
Springer; 2017, View Article : Google Scholar
|
|
17
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang LC, Xylinas E, Kent MT, Kluth LA,
Rink M, Jamzadeh A, Rieken M, Al Hussein Al Awamlh B, Trinh QD, Sun
M, et al: Combining smoking information and molecular markers
improves prognostication in patients with urothelial carcinoma of
the bladder. Urol Oncol. 32:433–440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xylinas E, Kluth LA, Lotan Y, Daneshmand
S, Rieken M, Karakiewicz PI and Shariat SF: Blood- and tissue-based
biomarkers for prediction of outcomes in urothelial carcinoma of
the bladder. Urol Oncol. 32:230–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Valentini V, van Stiphout RG, Lammering G,
Gambacorta MA, Barba MC, Bebenek M, Bonnetain F, Bosset JF, Bujko
K, Cionini L, et al: Nomograms for predicting local recurrence,
distant metastases, and overall survival for patients with locally
advanced rectal cancer on the basis of European randomized clinical
trials. J Clin Oncol. 29:3163–3172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Balachandran VP, Gonen M, Smith JJ and
DeMatteo RP: Nomograms in oncology: More than meets the eye. Lancet
Oncol. 16:e173–e80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim MS, Lee SY, Lee TR, Cho WH, Song WS,
Koh JS, Lee JA, Yoo JY and Jeon DG: Prognostic nomogram for
predicting the 5-year probability of developing metastasis after
neo-adjuvant chemotherapy and definitive surgery for AJCC stage II
extremity osteosarcoma. Ann Oncol. 20:955–960. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Al-Daghmin A, English S, Kauffman EC, Din
R, Khan A, Syed JR, Sztorc J, Mehedint D, Sharif M, Shi Y, et al:
External validation of preoperative and postoperative nomograms for
prediction of cancer-specific survival, overall survival and
recurrence after robot-assisted radical cystectomy for urothelial
carcinoma of the bladder. BJU Int. 114:253–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brooks M, Godoy G, Sun M, Shariat SF,
Amiel GE and Lerner SP: External validation of bladder cancer
predictive nomograms for recurrence, cancer-free survival and
overall survival following radical cystectomy. J Urol. 195:283–289.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishioka J, Saito K, Sakura M, Yokoyama M,
Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Kawakami S and
Kihara K: Development of a nomogram incorporating serum C-reactive
protein level to predict overall survival of patients with advanced
urothelial carcinoma and its evaluation by decision curve analysis.
Br J Cancer. 107:1031–1036. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujii N, Hoshii Y, Hirata H, Mori J,
Shimizu K, Kobayashi K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H,
et al: Impact of divergent differentiation in urothelial carcinoma
on oncological outcome in patients with T1 high-grade bladder
cancer. Jpn J Clin Oncol. 47:560–567. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Merrill RM and Johnson E: Benefits of
marriage on relative and conditional relative cancer survival
differ between males and females in the USA. J Cancer Surviv.
11:578–589. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chamie K, Litwin MS, Bassett JC, Daskivich
TJ, Lai J, Hanley JM, Konety BR and Saigal CS; Urologic Diseases in
America Project, : Recurrence of high-risk bladder cancer: A
population-based analysis. Cancer. 119:3219–3227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abdollah F, Gandaglia G, Thuret R,
Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF,
Perrotte P, et al: Incidence, survival and mortality rates of
stage-specific bladder cancer in United States: A trend analysis.
Cancer Epidemiol. 37:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brookfield KF, Cheung MC, Gomez C, Yang R,
Nieder AM, Lee DJ and Koniaris LG: Survival disparities among
African American women with invasive bladder cancer in Florida.
Cancer. 115:4196–4209. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mallin K, David KA, Carroll PR, Milowsky
MI and Nanus DM: Transitional cell carcinoma of the bladder: Racial
and gender disparities in survival (1993 to 2002), stage and grade
(1993 to 2007). J Urol. 185:1631–1636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ward EM, Fedewa SA, Cokkinides V and Virgo
K: The association of insurance and stage at diagnosis among
patients aged 55 to 74 years in the national cancer database.
Cancer J. 16:614–621. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weiss C, Ott OJ, Wittlinger M, Krause SF,
Fietkau R, Sauer R and Rödel C: Treatment options for high-risk T1
bladder cancer: Status quo and future perspectives of
radiochemotherapy. Strahlenther Onkol. 184:443–449. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vartolomei MD, Ferro M, Cantiello F,
Lucarelli G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, De
Berardinis E, Damiano R, et al: Validation of
neutrophil-to-lymphocyte ratio in a multi-institutional cohort of
patients with T1G3 non-muscle-invasive bladder cancer. Clin
Genitourin Cancer. 16:445–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Canter D, Egleston B, Wong YN, Smaldone
MC, Simhan J, Greenberg RE, Uzzo RG and Kutikov A: Use of radical
cystectomy as initial therapy for the treatment of high-grade T1
urothelial carcinoma of the bladder: A SEER database analysis. Urol
Oncol. 31:866–870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aziz A, May M, Burger M, Palisaar RJ,
Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, et al:
Prediction of 90-day mortality after radical cystectomy for bladder
cancer in a prospective European multicenter cohort. Eur Urol.
66:156–163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shabsigh A, Korets R, Vora KC, Brooks CM,
Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW and
Donat SM: Defining early morbidity of radical cystectomy for
patients with bladder cancer using a standardized reporting
methodology. Eur Urol. 55:164–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gontero P, Sylvester R, Pisano F, Joniau
S, Oderda M, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes
AJ, et al: The impact of re-transurethral resection on clinical
outcomes in a large multicentre cohort of patients with T1
high-grade/Grade 3 bladder cancer treated with bacille
Calmette-Guérin. BJU Int. 118:44–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fritsche HM, Burger M, Svatek RS, Jeldres
C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y,
Isbarn H, et al: Characteristics and outcomes of patients with
clinical T1 grade 3 urothelial carcinoma treated with radical
cystectomy: Results from an international cohort. Eur Urol.
57:300–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Soria F, Marra G, D'Andrea D, Gontero P
and Shariat SF: The rational and benefits of the second look
transurethral resection of the bladder for T1 high grade bladder
cancer. Transl Androl Urol. 8:46–53. 2019. View Article : Google Scholar : PubMed/NCBI
|
